RxDoctor Payments Data

Alan David Perry, MD

Family Medicine · Atlanta, GANPI 1679563423

Payments from drug & device makers

$8,452in general payments, 2019–2025

Across 412 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$1K
  • Gilead$1K
  • Novo Nordisk$929
  • Abbott$731
  • Lilly USA, LLC$666
  • Pfizer$411
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,452 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$67,910
Medicare patients
224
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen48$196,003
BiktarvyBictegrav/Emtricit/Tenofov Ala37$143,932
EliquisApixaban41$55,413
OzempicSemaglutide28$55,052
TriumeqAbacavir/Dolutegravir/Lamivudi11$47,419
JanuviaSitagliptin Phosphate27$39,887
MounjaroTirzepatide26$37,541
JardianceEmpagliflozin20$29,153
Janumet XrSitagliptin Phos/Metformin Hcl20$19,393
XareltoRivaroxaban21$17,093
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,046
TradjentaLinagliptin11$10,804
Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df12$2,963
Bupropion XlBupropion Hcl115$2,942
Atorvastatin Calcium319$2,656

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy$1,372$339,93585 claims
MerckJanuvia, Janumet Xr$391$59,28047 claims
PfizerEliquis, Paxlovid$411$56,84257 claims
Novo NordiskOzempic$929$55,05228 claims
Viiv Healthcare CompanyTriumeq$1,496$47,41911 claims
Boehringer IngelheimJardiance, Tradjenta$126$39,95631 claims
Lilly USA, LLCMounjaro$666$37,54126 claims
Johnson & JohnsonXarelto$203$17,09321 claims
GSKTrelegy Ellipta$137$16,04618 claims
Sanofi-aventis U.S. LLCLantus$106$1,46711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →